ArticleBlood advances2024
It is feasible and safe to stop specialized follow-up of asymptomatic lower-risk chronic lymphocytic leukemia.
Christian Brieghel et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
3 papers cite it
this papercites it